Monoclonal Gammopathy of Undetermined Significance

Link to article at PubMed

Ann Intern Med. 2022 Dec;175(12):ITC177-ITC192. doi: 10.7326/AITC202212200. Epub 2022 Dec 13.

ABSTRACT

Monoclonal gammopathy of undetermined significance (MGUS) is of considerable clinical importance to primary care physicians given its high prevalence in the general population. MGUS has a variable but lifelong risk for progression to hematologic cancer, such as multiple myeloma, Waldenström macroglobulinemia, or light-chain amyloidosis. In addition, MGUS has been associated with several nonmalignant yet symptomatic disorders that require therapy directed toward eliminating the monoclonal gammopathy. Thus, it is important not only to understand the essentials of diagnosing and monitoring patients with MGUS but also to recognize when to refer patients with MGUS to a specialist.

PMID:36508741 | DOI:10.7326/AITC202212200

Leave a Reply

Your email address will not be published. Required fields are marked *